Category Archives: Genetic Engineering

PUBLIC RELEASE DATE:

24-Apr-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, April 24, 2014D-ribose is a commercially important sugar used as a sweetener, a nutritional supplement, and as a starting compound for synthesizing riboflavin and several antiviral drugs. Genetic engineering of Escherichia coli to increase the bacteria's ability to produce D-ribose is a critical step toward achieving more efficient industrial-scale production of this valuable chemical, as described in an article in Industrial Biotechnology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Industrial Biotechnology website.

In "Engineering Escherichia coli for D-Ribose Production from Glucose-Xylose Mixtures." Pratish Gawand and Radhakrishnan Mahadevan, University of Toronto, Canada, describe the metabolic engineering strategy they used to increase the yield of D-ribose from the genetically modified E. coli, which were able to produce D-ribose from mixtures of glucose and xylose. The authors propose future research directions for additional metabolic engineering and bioprocess optimization.

"The research article by Gawand and Mahadevan represents one of many ways that molecular biology is being deployed to expand Industrial Biotechnology development," says Co-Editor-in-Chief Larry Walker, PhD, Professor, Biological & Environmental Engineering, Cornell University, Ithaca, NY.

###

About the Journal

Industrial Biotechnology, led by Co-Editors-in-Chief Larry Walker, PhD, and Glenn Nedwin, PhD, MoT, CEO and President, Taxon Biosciences, Tiburon, CA, is an authoritative journal focused on biobased industrial and environmental products and processes, published bimonthly in print and online. The Journal reports on the science, business, and policy developments of the emerging global bioeconomy, including biobased production of energy and fuels, chemicals, materials, and consumer goods. The articles published include critically reviewed original research in all related sciences (biology, biochemistry, chemical and process engineering, agriculture), in addition to expert commentary on current policy, funding, markets, business, legal issues, and science trends. Industrial Biotechnology offers the premier forum bridging basic research and R&D with later-stage commercialization for sustainable biobased industrial and environmental applications.

About the Publisher

Read more:
Engineered E. coli produces high levels of D-ribose as described in Industrial Biotechnology journal

4 hours ago 2014, Mary Ann Liebert, Inc., publishers

D-ribose is a commercially important sugar used as a sweetener, a nutritional supplement, and as a starting compound for synthesizing riboflavin and several antiviral drugs. Genetic engineering of Escherichia coli to increase the bacteria's ability to produce D-ribose is a critical step toward achieving more efficient industrial-scale production of this valuable chemical, as described in an article in Industrial Biotechnology.

In "Engineering Escherichia coli for D-Ribose Production from Glucose-Xylose Mixtures." Pratish Gawand and Radhakrishnan Mahadevan, University of Toronto, Canada, describe the metabolic engineering strategy they used to increase the yield of D-ribose from the genetically modified E. coli, which were able to produce D-ribose from mixtures of glucose and xylose. The authors propose future research directions for additional metabolic engineering and bioprocess optimization.

"The research article by Gawand and Mahadevan represents one of many ways that molecular biology is being deployed to expand Industrial Biotechnology development," says Co-Editor-in-Chief Larry Walker, PhD, Professor, Biological & Environmental Engineering, Cornell University, Ithaca, NY.

Explore further: Metabolically engineered E. coli producing phenol

More information: The article is available on the Industrial Biotechnology website.

Many chemicals we use in everyday life are derived from fossil resources. Due to the increasing concerns on the use of fossil resources, there has been much interest in producing chemicals from renewable resources through ...

The production of rare sugars has been very costly until now. A recent doctoral study indicates that their production can be made significantly more efficient with the help of genetically modified bacteria. ...

Food spoiling and poisoning caused by microbial contamination can cause major health, social, and economic problems. The broad scope of antimicrobial approaches to kill or prevent the growth of microorganisms ...

Combining systems metabolic engineering and downstream process, bio-based production of 5-aminovaleric acid and glutaric acid, important C5 platform chemicals, engineered in Escherichia coli could be demonstrated for the ...

Link:
Engineered E. coli produces high levels of D-ribose

SAN DIEGO Karl Deisseroth is having a very early breakfast before the day gets going at the annual meeting of the Society for Neuroscience. Thirty thousand people who study the brain are here at the Convention Center, a small citys worth of badge-wearing, networking, lecture-attending scientists.

For Deisseroth, though, this crowd is a bit like the gang at Cheers everybody knows his name. He is a Stanford psychiatrist and a neuroscientist, and one of the people most responsible for the development of optogenetics, a technique that allows researchers to turn brain cells on and off with a combination of genetic manipulation and pulses of light.

An online service is needed to view this article in its entirety. You need an online service to view this article in its entirety.

Or, use your linked account:

Unlimited access to SantaFeNewMexican.com and PasatiempoMagazine.comon your computer, smart phone and tablet.

Unlimted access to SantaFeNewMexican.com and PasatiempoMagazine.comon your computer, smart phone and tablet PLUS 7-Day home delivery of The New Mexican.

*Must reside within SFNM home delivery area. RATES DO NOT APPLY IN PLACITAS, RIBERA, ILFIELD OR VILLNUEVA. PLEASE CALL 800-873-3372 FOR MORE INFORMATION.

Unlimted access to SantaFeNewMexican.com and PasatiempoMagazine.comon your computer, smart phone and tablet PLUS Weekend home delivery of The New Mexican.

*Must reside within SFNM home delivery area. THESE RATES DO NOT APPLY IN PLACITAS, RIBERA, ILFIELD OR VILLNUEVA. PLEASE CALL 800-873-3372 FOR MORE INFORMATION.

Unlimted access to SantaFeNewMexican.com and PasatiempoMagazine.comon your computer, smart phone and tablet PLUS Sunday home delivery of The New Mexican.

See original here:
On-off switch for neurons allows scientists a deeper look into the brain

PUBLIC RELEASE DATE:

22-Apr-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, April 22, 2014Hemoglobin A1c is the standard measurement for assessing glycemic control over time in people with diabetes. Blood levels of A1c are typically measured every few months in a laboratory, but now researchers have developed a data-based model that accurately estimates A1c using self-monitored blood glucose (SMBG) readings, as described in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website at http://www.liebertpub.com/dtt.

In "Accuracy and Robustness of Dynamical Tracking of Average Glycemia (A1c) to Provide Real-Time Estimation of Hemoglobin A1c Using Routine Self-Monitored Blood Glucose Data," authors Boris Kovatchev, PhD, Frank Flacke, PhD, Jochen Sieber, MD, and Marc Breton, PhD present the computer algorithm they developed based on a training data set drawn from 379 subjects and then evaluated for accuracy on an independent test data set. The authors propose that estimation of real-time A1c could increase individuals' motivation to improve diabetes control.

"Patients are used to an A1c result from their doctor visits, and this study highlights simple estimated A1c values from SMBG data," says Satish Garg, MD, Editor-in-Chief of Diabetes Technology & Therapeutics and Professor of Medicine and Pediatrics at the University of Colorado Denver. "This may become an important tool for improved patient self-management."

###

About the Journal

Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of content and a sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website at http://www.liebertpub.com/dtt. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.

About ATTD

Read more here:
Routine blood glucose measurements can accurately estimate hemoglobin A1c in diabetes

By Laurel Maloy, contributing author, Food Online

Vermont House Bill H. 0112, legislature relating to the labeling of food produced with genetic engineering, is close to becoming law

Consumers across the nation, as well as 50 bill sponsors, are awaiting final passage of House Bill H. 0112. The bill passed the Vermont House last year, but has been waiting for the Vermont Senate to make changes. The bill is now on its way back to the House and, if approved, will head to the governors desk. Governor Peter Shumlin has indicated that he will most likely sign it. If all goes according to plan, the new law will take effect on Jul 1, 2016.

Vermont House Bill H. 0112:

Ronnie Cummins, National Director of the Organic Consumers Association said, Todays victory has been 20 years in the making! He elaborated by reminding everyone that since the early 1990s, when GMOs were first introduced, U.S. consumers have fought for GMO labeling.

Unlike neighbors Maine and Connecticuts bills, Vermonts has no contingency clause. Vermonts bill will not be contingent upon its neighbors passing similar legislation. However, this victory may be short lived. U.S. Rep. Mike Pompeo (R-KS) introduced a bill in the U.S. House of Representatives last week. If passed, the Safe and Accurate Food Labeling Act would not only prohibit mandatory GMO labeling, but would also forbid states from drafting their own statutes.

In recent years, several states have attempted to pass GMO labeling legislation but failed due to the interference of large, well-funded industry groups. In California and Washington State, the Coalition for Safe and Affordable Food reportedly spent some $60 million fighting GMO labeling initiatives. Its membership roster reads like the Whos Who of U.S. and global food processing. Its members include such industry power hitters as: Biotechnology Industry Organization, the American Soybean Association, the National Council of Farmer Cooperatives, and the National Grain & Feed Association. All of its 35 listed members have an economic interest in defeating GMO labeling initiatives and have the money and influence to keep it from happening.

The question consumers must be asking themselves is, why? If GMOs are truly safe, why are these groups so determined to defeat legislation that simply identifies those products containing GMOs? Recently, some large-scale retailers have demonstrated their support for the consumer, and are encouraging others to follow suit. It seems that even the industry big-wigs cannot come to a consensus on the safety of genetically-modified food products.

Read the original post:
Vermont Will Be The First State To Require Mandatory GMO Labeling

Geneshaft - episode 04 - ep 4 [ ENG SUB ]
Geneshaft https://www.youtube.com/watch?v=TvxxvqBzNVI list=PL0421PZsH4UIeqzHZWqy6zrM3wQJ2TjaV In the 21st century mankind was on the brink of destruction. Th...

By: Cluster Edge

See the article here:
Geneshaft - episode 04 - ep 4 [ ENG SUB ] - Video

Geneshaft - episode 11 - ep 11 [ ENG SUB ]
Geneshaft https://www.youtube.com/watch?v=TvxxvqBzNVI list=PL0421PZsH4UIeqzHZWqy6zrM3wQJ2TjaV In the 21st century mankind was on the brink of destruction. Th...

By: Cluster Edge

Link:
Geneshaft - episode 11 - ep 11 [ ENG SUB ] - Video

Geneshaft - episode 07 - ep 7 [ ENG SUB ]
Geneshaft https://www.youtube.com/watch?v=TvxxvqBzNVI list=PL0421PZsH4UIeqzHZWqy6zrM3wQJ2TjaV In the 21st century mankind was on the brink of destruction. Th...

By: Cluster Edge

The rest is here:
Geneshaft - episode 07 - ep 7 [ ENG SUB ] - Video

Journalism C101 - 2014-04-14: Pamela Ronald: Plant Genetic Engineering and
Journalism C101, 001 - Spring 2014 Creative Commons 3.0: Attribution-NonCommercial-NoDerivs.

By: UCBerkeley

Here is the original post:
Journalism C101 - 2014-04-14: Pamela Ronald: Plant Genetic Engineering and - Video

PUBLIC RELEASE DATE:

17-Apr-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, April 17, 2014The development of stem cell therapies to cure a variety of diseases depends on the ability to characterize stem cell populations based on cell surface markers. Researchers from the Finnish Red Cross have discovered a new marker that is highly expressed in a type of stem cells derived from human umbilical cord blood, which they describe in an article in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the BioResearch Open Access website.

Heli Suila and colleagues, Finnish Red Cross Blood Service, Helsinki, Finland present evidence to show that the glycan O-GLcNAc, is present on the surface of stem cells and is part of a stem cell-specific surface signature. In the article "Extracellular O-Linked N-Acetylglucosamine Is Enriched in Stem Cells Derived from Human Umbilical Cord Blood" the authors suggest that the glycan plays a crucial role in a cell signaling pathway that regulates embryonic development.

"This work is particularly interesting as epidermal growth factor domains are found on the Notch receptors, suggesting that these novel glycans may be involved in Notch receptor signaling pathways in stem cells," says BioResearch Open Access Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Advanced Cell Technology, Inc. and Editor Jane Taylor, PhD. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResearch Open Access website.

About the Publisher

Visit link:
Novel marker discovered for stem cells derived from human umbilical cord blood